M. Jannuzzo

发表

The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women

M. Rocchetti, I. Poggesi, P. Buchan, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of Reboxetine in Volunteers with Hepatic Impairment

G. Houin, P. Rampal, J. Fleishaker, 2000 .

Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone

P. Buchan, A. Bello, E. Salle, 2009, Breast Cancer Research and Treatment.

Pharmacokinetics of Single‐Dose Reboxetine in Volunteers with Renal Insufficiency

G. Houin, F. Fiorentini, I. Poggesi, 2000, Journal of clinical pharmacology.

Pharmacokinetics of the enantiomers of indoprofen in man.

F. B. Nicolis, E. Moro, V. Tamassia, 1984, International journal of clinical pharmacology research.

The dispositional enantioselectivity of indobufen in rat and mouse.

R. Roncucci, J. Caldwell, M. Strolin Benedetti, 1990, Biochemical pharmacology.

Hemodynamic effects of reboxetine in healthy male volunteers

I. Poggesi, T. Denolle, C. Pellizzoni, 1999, Clinical pharmacology and therapeutics.

Dose proportionality of reboxetine enantiomers in healthy male volunteers

I. Poggesi, P. Dostert, E. Rey, 1999, Biopharmaceutics & drug disposition.

Pharmacokinetics and tolerance of a new penem antibiotic, FCE 22101, in healthy volunteers after a single intravenous dose

M. Mandelli, M. Strolin Benedetti, D. Sassella, 2004, European Journal of Clinical Pharmacology.

High-performance liquid chromatographic method for pharmacokinetic studies on the new anthracycline 4-demethoxydaunorubicin and its 13-dihydro derivative.

V. Bellotti, E. Moro, G. Valzelli, 1983, Journal of chromatography.

Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma

M. Rocchetti, P. Nygren, N. Sarapa, 2003, Cancer Chemotherapy and Pharmacology.

Randomized phase II study of danusertib in patients with metastatic castration‐resistant prostate cancer after docetaxel failure

F. Cappuzzo, C. Sternberg, E. Raymond, 2013, BJU international.

A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation.

M. Rocchetti, I. Poggesi, D. Verotta, 2005, British journal of clinical pharmacology.

Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II

T. Gauler, A. Santoro, M. D. de Jonge, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Determination of 4'-epidoxorubicin and its 13-dihydro derivative in human plasma by high-performance liquid chromatography with fluorescence detection.

M. Ranghieri, E. Moro, G. Valzelli, 1982, Journal of chromatography.

Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors

F. Caponigro, F. Fiorentini, S. Crippa, 2010, Cancer Chemotherapy and Pharmacology.

Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC).

E. Smit, S. Novello, T. Gauler, 2013 .

Pharmacokinetics (PK) of Aromasin® (exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV)

P. Marrari, I. Poggesi, R. Spinelli, 1999 .

Estrogen suppression of 8-week treatment with exemestane combined with triptorelin versus triptorelin alone in healthy premenopausal women.

P. Buchan, E. di Salle, N. Pirotta, 2004, Journal of Clinical Oncology.

Phase II exploratory study of brostallicin in patients with ovarian cancer resistant/refractory to platinum-based chemotherapy

G. Scambia, G. Ferrandina, D. Lorusso, 2008 .

Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC).

M. Mariani, S. Tagawa, J. Bleuse, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC).

C. Barone, A. Santoro, M. D. Jonge, 2010 .

Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC).

I. Vergote, P. Schöffski, J. Delord, 2010 .

Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors.

A. Tolcher, K. Papadopoulos, S. Crippa, 2010 .